Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. J Exp Med. 2020;217(1):e20190459.
Maracle CX, Agca R, Helder B, Meeuwsen JAL, Niessen HWM, Biessen EAL, et al. Noncanonical NF-κB signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction. Atherosclerosis. 2018;270:33–41.
Vavlukis M, Pop-Gjorcevab D, Poposka L, Sandevska E, Kedev S. Myocardial Infarction in Systemic Lupus Erythematosus - the Sex-Specific Risk Profile. Curr Pharm Des. 2021;27(29):3221–8.
Restivo V, Candiloro S, Daidone M, Norrito R, Cataldi M, Minutolo G, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2021;21(1):102925.
Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59(2):345–64.
Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(11):2048–55.
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–15.
Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022;400(10354):733–43.
Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(29):e4272.
Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385–438.
Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain R, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(2):290–301.
Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 2007;56(5):1384–96.
Al-Soudi A, Kaaij MH, Tas SW. Endothelial cells: From innocent bystanders to active participants in immune responses. Autoimmun Rev. 2017;16(9):951–62.
Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood. 2012;119(24):5859–70.
Mak A, Kow NY, Schwarz H, Gong L, Tay SH, Ling LH. Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. Sci Rep. 2017;7(1):7320.
Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–33.
Theodorou K, Boon RA. Endothelial cell metabolism in atherosclerosis. Front Cell Dev Biol. 2018;6:82.
Teixeira V, Tam LS. Novel Insights in systemic lupus erythematosus and atherosclerosis. Front Med (Lausanne). 2017;4:262.
Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE–mechanisms and management. Nat Rev Rheumatol. 2012;8(4):214–23.
Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794–802.
Schonenberg-Meinema D, Bergkamp SC, Nassar-Sheikh Rashid A, van der Aa LB, de Bree GJ, Ten Cate R, Cutolo M, Hak AE, Hissink Muller PC, van Onna M, Kuijpers TW, Smith V, van den Berg JM. Nailfold capillary abnormalities in childhood-onset systemic lupus erythematosus: a cross-sectional study compared with healthy controls. Lupus. 2021;30(5):818–27.
Bergkamp SC, Schonenberg-Meinema D, Nassar-Sheikh Rashid A, Melsens K, Vanhaecke A, Boumans MJH, et al. Reliable detection of subtypes of nailfold capillary haemorrhages in childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol. 2021;39:1126.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
NIH QA. National Institutes of Health (2014). Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Available online at: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort. (Accessed Dec 2020). 2020.
Stock W. Statistical Methods for Meta-Analysi’s:Larry V. Hedges and Ingram Olkin Orlando FL: Academic Press, 1985, 369 pp., approx. $49.00. Appl Psychol Meas. 1987;11(1):104–6.
Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of meta-essentials: a free and simple tool for meta-analysis. Res Synth Methods. 2017;8(4):537–53.
Sánchez-Meca J, Marín-Martínez F. Confidence intervals for the overall effect size in random-effects meta-analysis. Psychol Methods. 2008;13(1):31–48.
el-Gamal YM, Heshmat NM, el-Kerdany TH, Fawzy AF. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Allergy Immunol. 2004;15(3):270–7.
Heshmat NM, El-Kerdany TH. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus. Pediatr Allergy Immunol. 2007;18(4):346–53.
Elhelaly N, Elhawary I, Alaziz I, Alsalam M, Elfishawy H, Sherif M. The clinical utility of vascular endothelial growth factor as predictive marker for systemic lupus erythematosus activity in children and adolescents. J Biol Sci. 2009;9(6):549–54.
Sahin S, Adrovic A, Barut K, Durmus S, Gelisgen R, Uzun H, et al. Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus. Lupus. 2017;26(10):1089–94.
Zhang CX, Cai L, Shao K, Wu J, Zhou W, Cao LF, et al. Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus. Pediatr Nephrol. 2018;33(5):837–45.
Lee WF, Wu CY, Yang HY, Lee WI, Chen LC, Ou LS, et al. Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous. Pediatr Rheumatol Online J. 2019;17(1):69.
Mostmans Y, Cutolo M, Giddelo C, Decuman S, Melsens K, Declercq H, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev. 2017;16(8):774–86.
Cook-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal. 2011;15(6):1607–38.
Jośko J, Gwóźdź B, Jedrzejowska-Szypułka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit. 2000;6(5):1047–52.
Camaré C, Pucelle M, Nègre-Salvayre A, Salvayre R. Angiogenesis in the atherosclerotic plaque. Redox Biol. 2017;12:18–34.
Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol. 1998;139(6):1049–51.
Boehme MW, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol. 2000;119(1):189–95.
Nakano T, Kawamoto K, Higashino K-i, Arita H. Prevention of growth arrest-induced cell death of vascular smooth muscle cells by a product of growth arrest-specific gene, gas6. FEBS Lett. 1996;387(1):78–80.
Laurance S, Lemarié CA, Blostein MD. Growth arrest-specific gene 6 (gas6) and vascular hemostasis. Adv Nutr. 2012;3(2):196–203.
Wu Q, Guan SY, Dan YL, Zhao CN, Mao YM, Liu LN, et al. Circulating pentraxin-3 levels in patients with systemic lupus erythematosus: a meta-analysis. Biomark Med. 2019;13(16):1417–27.
Fridell YW, Villa J Jr, Attar EC, Liu ET. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem. 1998;273(12):7123–6.
Kim HA, Nam JY, Jeon JY, An JM, Jung JY, Bae CB, et al. Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus. J Clin Immunol. 2013;33(1):143–50.
Shimada Y, Asanuma YF, Yokota K, Yoshida Y, Kajiyama H, Sato K, et al. Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus. Mod Rheumatol. 2014;24(1):78–85.
Comments (0)